ClinicalTrials.gg
CompletedNCT01614366Updated Nov 13, 2015

DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension

A Phase 2 interventional study of AM 5 + DM 0 and AM 5 + DM 2.5 in Hypertension, sponsored by TSH Biopharm Corporation Limited. Completed at 8 sites in Taiwan. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-11-13.

Sponsored by TSH Biopharm Corporation Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Non-randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 116 studies in Hypertension with a site in Taiwan — 17 open to participants now, 20 under way, 5 of them phase 3. Hypertension · Taiwan.

Enrollment
60th of 90
111 · median 233
Started
2012
with 5 others
Phase 2
12 of 116
none open now
Registered
49th of 116
by date

Among the 116 studies in Hypertension with a site in Taiwan, this one is the 60th largest by enrollment of the 90 interventional ones that give a count, is one of 6 that started in 2012, is one of 12 in phase 2, and was the 49th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

17 of the 116 studies in Hypertension with a site in Taiwan are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Hypertension with a site in Taiwan, or all of them as a file.
02

Study summary

The purpose of this study is to compare the different dose of DMTA07 (DM) combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.

Read the detailed description

To compare the different dose of DM combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.

The purpose of this study is to compare the antihypertensive efficacy and tolerability of different dose of DM combines with amlodipine treatment, further to explore the optimized combination dose of DM.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • amlodipine
  • DMTA07
  • hypertension
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient aged between 50 to 75 years old (both included);
  2. Patient with mild to moderate essential hypertension at enrollment, which defined as the following:

    Patient must have mean sitting SBP ≥140 and \<180 mmHg or mean sitting DBP ≥90 and \<110 mmHg at enrollment;

  3. Patient with normal serum potassium;
  4. Patient or his/her legally acceptance representative has signed the written form.

Exclusion criteria

Exclusion Criteria:

  1. Patient with severe hypertension (mean sitting DBP ≥ 110 mmHg or mean sitting SBP ≥ 180 mmHg);
  2. Patient with secondary hypertension, such as coarctation of aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc;
  3. Patient is under treatment with beta-blocker prior to enrollment;
  4. A definite diagnosis or unstable of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, , stroke, arrhythmia and heart failure within 3 months before signing the written form;
  5. Patient with concomitant endocrine diseases or type 1 Diabetes Mellitus;
  6. Patient with type 2 Diabetes Mellitus with poor glucose control (glycosylated > 9% or fasting blood sugar > 250 mg/dL at enrollment) or under insulin treatment;
  7. Patient with clinically unstable disease such as known collagen or auto-immune disease or other malignant disease requiring current medication;
  8. Patient with bilateral renal artery stenosis, solitary kidney or post renal transplant;
  9. Patient with hematological disease;
  10. Hepatic or renal dysfunction as defined by the following parameters:

    • or AST > 2 times ,
    • Total > 2 times upper limit of normal,
    • Serum creatinine >2.0 mg/dl;
  11. Female patient who is pregnant or lactating;
  12. Patient with substance abuse (including alcohol) history for the past two years;
  13. Known or suspected , including allergy to DMTA07 or calcium channel blockers;
  14. Patient received other drug or device within 30 days before signing the written informed consent form;
  15. Patient with any other serious disease considered by the investigator(s) not in the condition to enter the trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
Single (Participant)
Enrollment
111 participants (actual)

Study arms

  • Active comparator
    AM 5 + DM 0

    Amlodipine 5 mg + DMTA07 0mg, once daily

    Drug: AM 5 + DM 0

  • Experimental
    AM 5 + DM 2.5

    Amlodipine 5 mg + DMTA07 2.5mg, once daily

    Drug: AM 5 + DM 0 · Drug: AM 5 + DM 2.5

  • Experimental
    AM 5 + DM 7.5

    Amlodipine 5 mg + DMTA07 7.5mg, once daily

    Drug: AM 5 + DM 0 · Drug: AM 5 + DM 2.5 · Drug: AM 5 + DM 7.5

  • Experimental
    AM 5 + DM 30

    Amlodipine 5 mg + DMTA07 30mg, once daily

    Drug: AM 5 + DM 0 · Drug: AM 5 + DM 2.5 · Drug: AM 5 + DM 7.5 · Drug: AM 5 + DM 30

Interventions

  • DrugAM 5 + DM 0

    Amlodipine 5 mg + DMTA07 0mg, once daily

    Also known as: Amlodipine (AM), DMTA07 (DM)

  • DrugAM 5 + DM 2.5

    Amlodipine 5 mg + DMTA07 2.5mg, once daily

    Also known as: Amlodipine (AM), DMTA07 (DM)

  • DrugAM 5 + DM 7.5

    Amlodipine 5 mg + DMTA07 7.5mg, once daily

    Also known as: Amlodipine (AM), DMTA07 (DM)

  • DrugAM 5 + DM 30

    Amlodipine 5 mg + DMTA07 30mg, once daily

    Also known as: Amlodipine (AM), DMTA07 (DM)

06

What researchers measure

Primary outcomes

  1. *SBP reduction=SBP each visit- SBPvisit2

    The primary objective of this study is to compare the sitting systolic blood pressure (mmHg) reduction\* between four dose regimens, the baseline is defined as the actual SBP value after 2 weeks of amlodipine run-in period

    Time frame: 14 weeks

Secondary outcomes

  1. The secondary objectives of the study include: Efficacy/Safety

    Efficacy: To compare the sitting diastolic blood pressure (mmHg) reduction\* between four dose regimens, the baseline is defined as the actual DBP value after 2 weeks of amlodipine run-in period To evaluate the percentage of SBP reduction in four treatment regimens To evaluate the changes of blood pressure (mmHg) in different clusters; such as diabetes etc. Safety: To evaluate the pulse rate changes To evaluate incidences of adverse events To evaluate the change of laboratory test results from baseline

    Time frame: 14 weeks

07

Study locations

8 sites
  • E-DA Hospital
    Kaohsiung, 824, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Mackay Memorial Hospital
    Taipei, 104, Taiwan
  • Cheng Hsin General Hospital
    Taipei, 112, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
  • Tri-Service General Hospital
    Taipei, 114, Taiwan
  • Chang Gung Memorial Hospital
    Taoyuan County, 333, Taiwan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2012
First posted
Jun 7, 2012
Start
Jul 2012
Primary completionActual
May 2014
CompletionActual
May 2014
Last update
Nov 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01614366
Lead sponsor
TSH Biopharm Corporation Limited
Responsible party
Sponsor
First posted
Jun 7, 2012
Start date
Jul 2012
Primary completion
May 2014
Completion
May 2014
Last update
Nov 13, 2015

Study contacts

Jaw-Wen Chen, Doctor
principal investigator · VGHTP

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion